Mammakarzinom 2011 – Neue Aspekte

Zusammenfassung

Die Behandlungsoptionen und ebenfalls die Charakteristika zur Therapieentscheidung der Patientin mit einem primären und fortgeschrittenen Mammakarzinom werden immer vielfältiger. Neue zielgerichtete Therapien in Kombination mit etablierten Chemotherapien erweitern das Spektrum, doch potenziell vielversprechende Kombinationen erzielen nicht immer ein besseres Ergebnis. Neuste Daten aus der Pharmakogenomik weisen auf Prognose- und Prädiktivfaktoren hin, die nicht nur die Eigenschaften des Tumors, sondern außerdem die vererbbaren genetischen Eigenschaften der Patientin berücksichtigen. Die aktuelle Therapieentscheidung ist somit mittlerweile eine Kombination aus klassischerweise klinischen und modernen molekularen Biomarkern. Immer häufiger werden zusätzlich gesundheitsökonomische Aspekte berücksichtigt, sodass außerdem gesundheitspolitische Überlegungen eine Rolle spielen können. Diese Übersichtsarbeit baut auf den aktuellen Kongressen auf, die jedes Jahr stattfinden. Der letzte berücksichtigte ist hierbei die Jahrestagung der American Society of Clinical Oncology (ASCO) 2011 in Chicago.

Abstract

The treatment options for primary and metastatic breast cancer patients as well as the characteristics considered for therapy decision continue to become more diverse. New target therapies in combination with established chemotherapy regimens extend the range, however, potentially promising combinations do not always result in a benefit for the patient. Latest pharmacogenomics results hint towards prognosis and predictive factors, which do not only focus on the individual properties of the tumor, they also consider the hereditary genetics of the patient. As a result, state of the art therapy decision includes classical clinical as well as modern molecular biomarkers, however, pharmacoeconomic aspects continue to increase in importance in physicians' treatment algorithms. This review builds on the recent congresses, which present new data on the treatment of breast cancer. The last included one is the Annual Meeting of the American Society of Clinical Oncology (ASCO) 2011.

Schlüsselwörter

Mammakarzinom - Therapie - Prognose - molekulare Marker - Studien

Key words

breast cancer - therapy - prognosis - molecular marker - studies

Literatur

• 1 Kaufmann M, Rody A. Breast cancer: reduced mortality by early detection and adjuvant therapy.  Geburtsh Frauenheilk. 2009;  69 218-232
• 2 Beckmann M W, Blohmer J U, Costa S D et al. Zurich consensus: German expert opinion on the St. Gallen votes on 15 March 2009 (11th international conference at St. Gallen: primary therapy of early breast cancer) 2009 St. Gallen conference: primary therapy of early breast cancer – opinion among German experts (Zurich 2009).  Geburtsh Frauenheilk. 2009;  69 377-383
• 3 Diel I, Dresemann G, Fehm T et al. Interdisciplinary consensus on the use of adjuvant bisphosphonate therapy in breast cancer patients.  Geburtsh Frauenheilk. 2009;  69 511-516
• 4 Ruckhaberle E, Solbach C, Kaufmann M. Conference report on the 31st annual San Antonio breast cancer symposium, December 10-14, 2008 “Continuing change in diagnostics and therapy of breast cancers – from molecular basics to tailored therapy”.  Geburtsh Frauenheilk. 2009;  69 202-211
• 5 Ruckhaberle E, Rody A, Kaufmann M. Report of the 32nd annual San Antonio breast cancer symposium, December 10-13, 2009 “An international scientific symposium for interaction and exchange among basic scientists and clinicians in breast cancer”.  Geburtsh Frauenheilk. 2010;  70 177-183
• 6 Fasching P A, Fehm T, Janni W et al. Breast cancer therapy – a state of the art review.  Geburtsh Frauenheilk. 2010;  70 875-886
• 7 Kast K, Distler W, Schmutzler R. Current recommendations for the prevention and treatment of hereditary breast cancer.  Geburtsh Frauenheilk. 2010;  70 634-639
• 8 Goss P E, Ingle J N, Alés-Martínez J E et al. Exemestane for primary prevention of breast cancer in postmenopausal women: NCIC CTG MAP.3 – A randomized, placebo-controlled trial.  J Clin Oncol. 2011;  29 (Suppl.) Abstr. LBA 504
• 9 Goss P E, Ingle J N, Alés-Martínez J E et al. Exemestane for breast-cancer prevention in postmenopausal women.  N Engl J Med. 2011;  364 (25) 2381-2391
• 10 Meindl A, Ditsch N, Kast K et al. Familiäres Mamma- und Ovarialkarzinom.  Dtsch Arztebl Int. 2011;  108 (19) 323-330
• 11 Rebbeck T R, Friebel T, Wagner T et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE study group.  J Clin Oncol. 2005;  23 7804-7810
• 12 Petru E, Wildt L, Stummvoll W et al. Consensus of the Austrian Society for Gynecology and Obstetrics/Gynecologic Oncology Working Group. Fertility, contraception and hormone replacement therapy in oncologic patients with special reference to breast cancer.  Geburtsh Frauenheilk. 2009;  69 1071-1077
• 13 Domchek S M, Friebel T, Neuhausen S L et al. PROSE Consortium: Is hormone replacement therapy (HRT) following risk-reducing salpingo-oophorectomy (RRSO) in BRCA1 (B1)- and BRCA2 (B2)-mutation carriers associated with an increased risk of breast cancer?.  J Clin Oncol. 2011;  29 (Suppl.): Abstr 1501
• 14 TIME healthland .(6.6.2011). Im Internet:. http://healthland.time.com/2011/06/06/a-breast-cancer-treatment-works-as-prevention-too Stand: 15.6.2011
• 15 Whelan T J, Olivotto I, Ackerman I et al. NCIC-CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer.  J Clin Oncol. 2011;  29 (Suppl.): Abstr LBA1003
• 16 Untch M, Fasching P A, Konecny G E et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: Results from the TECHNO trial of the AGO and GBG study groups.  J Clin Oncol. 2011;  29 3351-3357
• 17 Gianni L, Eiermann W, Semiglazov V et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.  Lancet. 2010;  375 377-384
• 18 Wolff A C, Hammond M E, Schwartz J N et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.  Arch Pathol Lab Med. 2007;  131 18-43
• 19 Liedtke C, Wolf M K, Kiesel L. New concepts for targeted systemic therapy in breast cancer.  Geburtsh Frauenheilk. 2010;  70 625-633
• 20 Liedtke C, Kiesel L. Basal/triple negative breast cancer.  Geburtsh Frauenheilk. 2009;  69 309-315
• 21 Gluz O, Liedtke C, Nitz U et al. Molecular mechanisms of chemoresistance and potential means of overcoming it.  Geburtsh Frauenheilk. 2009;  69 138-144
• 22 Alba E, Chacon J I, Lluch A et al. Chemotherapy (CT) with or without carboplatin as neoadjuvant treatment in patients with basal-like breast cancer: GEICAM 2006-03-A multicenter, randomized phase II study.  J Clin Oncol. 2011;  29 (Suppl.): Abstr 1015
• 23 Gerber B, Eidtmann H, Rezai M et al. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 686 triple-negative primary breast cancers: Secondary endpoint analysis of the GeparQuinto study (GBG 44).  J Clin Oncol. 2011;  29 (Suppl.): Abstr 1006
• 24 von Minckwitz G, Eidtmann H, Rezai M et al. Neoadjuvant chemotherapy with or without Bevacizumab: Primary efficacy endpoint analysis of the GEPARQUINTO Study (GBG 44).  SABCS. 2010;  Abstract S4-S6
• 25 Bear H D, Tang G, Rastogi P et al. The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40.  J Clin Oncol. 2011;  29 (Suppl.): Abstr LBA1005
• 26 Gianni L, Pienkowski T, Im Y H et al. Neoadjuvant pertuzumab (P) and trastuzumab (H): antitumor and safety analysis of a randomized phase II study (‘NeoSphere ).  Cancer Res. 2010;  70 82s
• 27 Baselga J, Bradbury I, Eidtmann H et al. First results of the NeoALTTOtrial (BIG 01-06/EGF 106903): a phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER 2-positive primary breastcancer.  Cancer Res. 2010;  70 82s
• 28 Guarneri V, Frassoldati A, Bottini A et al. Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial).  J Clin Oncol. 2011;  29 (Suppl.): Abstr 507
• 29 Chang J C N, Mayer I A, Forero-Torres A et al. TBCRC006: A multicenter phase II study of neoadjuvant lapatinib and trastuzumab in patients with HER2-overexpressing breast cancer.  J Clin Oncol. 2011;  29 (Suppl.): Abstr 505
• 30 Holmes F A, Nagarwala Y M, Espina V A et al. Correlation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast cancer chemotherapy.  J Clin Oncol. 2011;  29 (Suppl.): Abstr 506
• 31 Felici A, Verweij J, Sparreboom A. Dosing strategies for anticancer drugs: the good, the bad and body-surface area.  Eur J Cancer. 2002;  38 (13) 1677-1684
• 32 Saarto T, Blomqvist C, Rissanen P et al. Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer.  Br J Cancer. 1997;  75 (2) 301-305
• 33 Poikonen P, Saarto T, Lundin J et al. Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF.  Br J Cancer. 1999;  80 (11) 1763-1766
• 34 Mayers C, Panzarella T, Tannock I F. Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma.  Cancer. 2001;  91 2246-2257
• 35 Cameron D A, Massie C, Kerr G et al. Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer.  Br J Cancer. 2003;  89 (10) 1837-1842
• 36 Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.  J Clin Oncol. 1996;  14 (9) 2590-2611
• 37 Bergh J, Wiklund T, Erikstein B et al. Tailored fluorouracil, epirubicin and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.  Lancet. 2000;  356 (9239) 1384-1391
• 38 Lindman H, Aström G, Ahlgren J et al. Individually tailored toxicity-based 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy of metastatic breast cancer.  Acta Oncol. 2007;  46 (2) 165-171
• 39 Iiristo M, Wiklund T, Wilking N et al. Tailored chemotherapy doses based on toxicity in breast cancer result in similar quality of life values, irrespective of given dose levels.  Acta Oncol. 2011;  50 338-343
• 40 Lindman H, Andersson M, Edlund P et al. A randomized study of individually tailored toxicity-based dosage of lluorouracil-epirubicin-cyclophosphamide chemotherapy (FEC) for early breast cancer (SBG 2000-1).  J Clin Oncol. 2011;  29 (Suppl.): Abstr 1017
• 41 Edlund P, Ahlgren J, Bjerre K et al. Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1.  Acta Oncol. 2011;  50 (3) 329-337
• 42 Citron M L, Berry D A, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.  J Clin Oncol. 2003;  21 (8) 1431-1439
• 43 Moebus V, Jackisch C, Lueck H et al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.  J Clin Oncol. 2010;  28 (17) 2874-2880
• 44 Moebus V, Thomssen C, Lueck H et al. Intense dose-dense (idd) sequential chemotherapy with epirubicin (E), paclitaxel (T), and cyclophosphamide (C) (ETC) compared with conventionally scheduled chemotherapy in high-risk breast cancer patients (> 3+LN): Eight-year follow-up analysis.  J Clin Oncol. 2011;  29 (Suppl.): Abstr 1018
• 45 Moebus V, Lueck H, Thomssen C et al. The impact of epoetin-alpha on anemia, red blood cell (RBC) transfusions, and survival in breast cancer patients (pts) treated with dose-dense sequential chemotherapy: Mature results of an AGO phase III study (ETC trial).  J Clin Oncol 2007; ASCO Annual Meeting Proceedings Part I. 2007;  25 (Suppl.) 569
• 46 Giordano S H, Lin Y, Kuo Y et al. Anthracyline (A) use among women with breast cancer (BC).  J Clin Oncol. 2011;  29 (Suppl.): Abstr 1019
• 47 Cheang M C U, Voduc D, Tu D et al. The responsiveness of intrinsic subtypes to adjuvant anthracyclines versus nonanthracyclines in NCIC.CTG MA.5 randomized trial.  J Clin Oncol. 2011;  29 (Suppl.): Abstr 1032
• 48 Rocca A, Paradiso A, Sismondi P et al. Benefit from CMF with or without anthracyclines in relation to biologic profiles in early breast cancer.  J Clin Oncol. 2011;  29 (Suppl.): Abstr 1031
• 49 Somlo G. Discussion: Triple-negative/Cytotoxics/Local Therapy.  J Clin Oncol. 2011;  (suppl.; discussion)
• 50 Henderson I C. Can we abandon anthracyclines for early breast cancer patients?.  Oncology. 2011;  25 (2) 115-124 127
• 51 NCCN-Guidelines™ Version 2.2011 Breast Cancer. Im Internet: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp%23site Stand: 15.6.2011
• 52 AGO-Leitlinie Mamma: Adjuvante Chemotherapie + Trastuzumab (Optimale Substanzen/Dosierung/Trastuzumab). Im Internet: http://www.ago-online.de/_download/unprotected/g_mamma_11_1_0_d_03_adjuvant_chemotherapy.pdf Stand: 15.6.2011
• 53 Gonzalez-Angulo A M, Litton J K, Broglio K R et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.  J Clin Oncol. 2009;  27 (34) 5700-5706
• 54 Piccart-Gebhart M J, Procter M, Leyland-Jones B et al. Herceptin adjuvant (HERA) trial study team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.  N Engl J Med. 2005;  353 (16) 1659-1672
• 55 Romond E H, Perez E A, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.  N Engl J Med. 2005;  353 (16) 1673-1684
• 56 Joensuu H, Isola J, Lundin M et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study.  Clin Cancer Res. 2003;  (3) 923-930
• 57 Rakkhit R et al. Significant increased recurrence rates among breast cancer patients with HER2-positive, T1a,bN0M0 tumors.  Cancer Res. 2009;  69 (Suppl.) 96 Abstr 701
• 58 Amar S, McCullough A E, Tan W et al. Prognosis and outcome of small (≤ 1 cm), node-negative breast cancer on the basis of hormonal and HER-2 status.  Oncologist. 2011;  15 1043-1049
• 59 Amar S, McCullough A E, Tan W et al. Prognosis and outcome of small (<=1 cm), node-negative breast cancer on the basis of hormonal and HER-2 status.  Oncologist. 2010;  15 (10) 1043-1049
• 60 Tovey S M et al. Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours.  Br J Cancer. 2009;  100 (5) 680-683
• 61 Pagani A et al. Clinical outcome of very small (< 1 cm) HER2-positive breast cancer and the role of trastuzumab as adjuvant treatment.  Ann Oncol. 2008;  19 ix87-ix102 Abstr. L2
• 62 Norris B, Chia S, Cheang M et al. Poor 10-year breast cancer – specific survival and relapsefree survival for HER2-positive T1N0 tumors.  Breast Cancer Res Treat. 2006;  100 S90
• 63 Chia S et al. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers.  J Clin Oncol. 2008;  26 5697-5704
• 64 Park Y, Kim S, Ok O et al. Risk stratification by hormonal receptor (ER, PgR) and HER2 status in small (≤ 1 cm) invasive breast cancer: Who might be a possible candidate for adjuvant treatment?.  J Clin Oncol. 2009;  27 (Suppl.) 15 Abstr 564
• 65 Chew H K, Brown M. Cause-specific and all-cause mortality of HER2-positive, node-negative, T1a and T1b breast cancers.  J Clin Oncol. 2010;  28 (Suppl.) 15 Abstr 583
• 66 Dall P, Hinke A, Lenzen G et al. Adjuvant treatment strategy and results in small breast cancer tumours (pT1) with HER2 overexpression.  J Clin Oncol. 2011;  29 (Suppl.): Abstr 607
• 67 Wassermann J, Albiges L, Rodrigues M J et al. Treatment of small node-negative HER2+ invasive breast carcinomas: Forty-month update of the joint Aerio/Remagus study.  J Clin Oncol. 2011;  29 (Suppl.): Abstr 557
• 68 Rodrigues M J, Wassermann J, Albiges L et al. Trastuzumab treatment in T1ab, node-negative, human epidermal growth factor receptor 2-overexpressing breast carcinomas.  J Clin Oncol. 2010;  28 (28) e541-542
• 69 Fehrenbacher L, Shiraz P, Sattavat M et al. T1abN0M0 HER2+ invasive breast cancer recurrence: Population-based cohort of 17,000 + consecutive breast cancers 2000–2006 at Kaiser Permanente Northern California (KPNC).  J Clin Oncol. 2011;  29 (Suppl.): Abstr 551
• 70 Cancello G, Maisonneuve P, Rotmensz N et al. Prognosis in women with small (T1mic, T1a, T1b) node-negative operable breast cancer by immunohistochemically selected subtypes.  J Clin Oncol. 2011;  29 (Suppl.): Abstr 546
• 71 O'Brien N A, Browne B C, Chow L et al. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.  Mol Cancer Ther. 2010;  9 (6) 1489-1502
• 72 Stemke-Hale K, Gonzalez-Angulo A M, Lluch A et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.  Cancer Res. 2008;  68 (15) 6084-6091
• 73 Saal L H, Johansson P, Holm K et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity.  Proc Natl Acad Sci USA. 2007;  104 (18) 7564-7569
• 74 Nagata Y, Lan K H, Zhou X et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.  Cancer Cell. 2004;  6 (2) 117-127
• 75 Dave B, Migliaccio I, Gutierrez M C et al. Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers.  J Clin Oncol. 2011;  29 (2) 166-173
• 76 Esteva F J, Guo H, Zhang S et al. PTEN, PIK3CA, p-AKT, and p-p 70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.  Am J Pathol. 2010;  177 (4) 1647-1656
• 77 Fabi A, Metro G, Di Benedetto A et al. Clinical significance of PTEN and p-Akt co-expression in HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.  Oncology. 2010;  78 (2) 141-149
• 78 Gori S, Sidoni A, Colozza M et al. EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.  Ann Oncol. 2009;  20 (4) 648-654
• 79 Yonemori K, Tsuta K, Shimizu C et al. Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy.  Med Oncol. 2009;  26 (3) 344-349
• 80 Perez E A, Suman V J, Davidson N E et al. Results of chemotherapy alone, with sequential or concurrent addition of 52 weeks of trastuzumab in the NCCTG N9831 HER2-positive adjuvant breast cancer Trial.  Cancer Res. 2009;  69 (Suppl.): Abstr 80
• 81 Perez E A, Reinholz M M, Hillman D W et al. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.  J Clin Oncol. 2010;  28 (28) 4307-4315
• 82 Perez E A, Dueck A C, Reinholz M M et al. Effect of PTEN protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG adjuvant trial N9831.  J Clin Oncol. 2011;  29 (Suppl.): Abstr 10504
• 83 Martin M, Martinez N, Ramos M et al. Randomized, phase II trial comparing continuous versus intermittent capecitabine (X) monotherapy for metastatic breast cancer (MBC): Results from the GEICAM 2009-05 study.  J Clin Oncol. 2011;  29 (Suppl.): Abstr 1008
• 84 Gluz O, Liedtke C, Kates R E et al. Molecular subtypes, body mass index (BMI), and their time-varying prognostic impact in node-positive breast cancer (BC): Pooled analysis from the WSG AM-01 and -02 trials.  J Clin Oncol. 2011;  29 (Suppl.): Abstr 1021
• 85 Pfeiler G, Königsberg R, Mlineritsch B et al. Effect of change of body mass index (BMI) during therapy on the efficacy of endocrine therapy in premenopausal patients with breast cancer: An analysis of the ABCSG-12 trial.  J Clin Oncol. 2011;  29 (Suppl.): Abstr 514
• 86 Dawood S S, Lei X, Litton J K et al. Effect of body mass index on survival outcome among women with early-stage, triple-negative breast cancer.  J Clin Oncol. 2011;  29 (Suppl.): Abstr 1130
• 87 Gennari A, Puntoni M, Nanni O et al. Body mass index (BMI) and prognosis in women with metastatic breast cancer (MBC).  J Clin Oncol. 2011;  29 (Suppl.): Abstr 566
• 88 Giuliano M, Giordano A, Patt A et al. Circulating tumor cells as a prognostic factor independent of obesity in metastatic breast cancer patients.  J Clin Oncol. 2011;  29 (Suppl.): Abstr 610
• 89 Gnant M, Mlineritsch B, Schippinger W et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer.  N Engl J Med. 2009;  360 679-691E
• 90 Eidtmann H, de Boer R, Bundred N et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study.  Ann Oncol. 2010;  21 2188
• 91 Coleman R E, Thorpe H C, Cameron D et al. AZURE (BIG 01/01) investigators. Adjuvant treatment with Zoledronic acid in stage II/III breast cancer. The AZURE trial (BIG 01/04).  SABCS. 2010;  Abstr 4–5
• 92 Gnant M, Mlineritsch B, Stoeger H et al. Overall survival with adjuvant zoledronic acid in patients with premenopausal breast cancer with complete endocrine blockade: Long-term results from ABCSG-12.  J Clin Oncol. 2011;  29 (Suppl.): Abstr 520
• 93 De la Haba J, Rodriguez-Lescure A, Baena J M et al. Final analysis of dose density with zoledronic acid treatment in metastatic breast cancer patients: ZARAS study.  J Clin Oncol. 2011;  29 (Suppl.): Abstr 630
• 94 De Censi A, Sun Z, Thurlimann B J K et al. Bone mineral density (BMD) in participants (pts) of trial BIG 1-98 comparing adjuvant letrozole (L) versus tamoxifen (T) or their sequence.  J Clin Oncol. 2011;  29 (Suppl.): Abstr 516
• 95 Perrone F, Gallo C, Lastoria S et al. Bone effects of adjuvant tamoxifen (T), letrozole (L), or L plus zoledronic acid (Z) in early breast cancer (EBC): The phase III HOBOE study.  J Clin Oncol. 2011;  29 (Suppl.): Abstr 517
• 96 Hershman D L, Cheung A M, Chapman J W et al. Effects of adjuvant exemestane versus anastrozole on bone mineral density: Two-year results of the NCIC CTG MA.27 bone companion study.  J Clin Oncol. 2011;  29 (Suppl.): Abstr 518
• 97 Enright K, Trudeau M E, Taback N et al. A population-based assessment of the risk of fragility fracture associated with the use of adjuvant hormone therapy for early breast cancer in older women.  J Clin Oncol. 2011;  29 (Suppl.): Abstr 519
• 98 Batouli P, Jahanshahi J B Y. Global cancer mortality: The effect of health care system resources on survival from cancer.  J Clin Oncol. 2011;  29 (Suppl.): Abstr 1576
• 99 Hassett M J, Neville B A, Weeks J C. The relationship between cost, quality, and outcomes among women with breast cancer in SEER–Medicare.  J Clin Oncol. 2011;  29 (Suppl.): Abstr 6001
• 100 Negro E G, Rivarola J, Gil E et al. Off-label prescriptions in cancer: Who should pay for them?.  J Clin Oncol. 2011;  29 (Suppl.): Abstr e16559
• 101 Touloukian E Z, Yakan A, Bloom R E. Antiemetic choice based on economic advantage.  J Clin Oncol. 2011;  29 (Suppl.): Abstr 9018
• 102 Garrison L P, Lalla D, Brammer M G et al. Assessing the potential cost-effectiveness of retesting IHC0, IHC1-positive, or FISH-negative early-stage breast cancer patients for HER2 status.  J Clin Oncol. 2011;  29 (Suppl.): Abstr 6133
• 103 Deenen M J, Cats A, Sechterberger M K et al. Safety, pharmacokinetics (PK), and cost-effectiveness of upfront genotyping of DPYD in fluoropyrimidine therapy.  J Clin Oncol. 2011;  29 (Suppl.): Abstr 3606
• 104 Nearchou D, Valachis A, Polyzos N P et al. Conflict of interest in economic analyses of targeted therapies in oncology.  J Clin Oncol. 2011;  29 (Suppl.): Abstr 6120
• 105 Carter J A, Snedecor S J, Kaura S et al. Cost-effectiveness of zoledronic acid (ZOL) versus denosumab (Dmab) in prevention of skeletal-related events (SREs) in metastatic breast cancer (mBC).  J Clin Oncol. 2011;  29 (Suppl.): Abstr 9025
• 106 Coyle D, Grunfeld E, Coyle K et al. Cost-effectiveness of a survivorship care plan for breast cancer survivors.  J Clin Oncol. 2011;  29 (Suppl.): Abstr 6082